PDYN

Across TCGA pan-cancer cohorts, PDYN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDYN data layer compared with 17 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PDYN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDYN expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

ACC, SCLC, and UCEC are the cancer types where PDYN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SCLC	DFS	Median	All	1.000	0.261	.016	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	II,III,IV	0.695	0.853	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDYN–ACC (DFS)

Open the ACC breakdown →